Highlights

  • Nyrada Inc. (ASX:NYR) has dosed the first patient in its Phase IIa PROTECT-MI trial evaluating Xolatryp in heart attack patients.
  • The trial is assessing whether Xolatryp can reduce tissue damage associated with ischaemia-reperfusion injury following emergency heart procedures.
  • PROTECT-MI is a randomised, double-blind and placebo-controlled study involving patients with ST-elevation myocardial infarction (STEMI).
  • Patient dosing has commenced at Nepean Hospital in New South Wales and Sir Charles Gairdner Hospital in Western Australia.
  • Nyrada expects final patient dosing around mid-2027, with topline results anticipated approximately three months after the final patient completes follow-up.

Nyrada Inc. (ASX:NYR) has reached a key clinical development milestone after dosing the first patient in its Phase IIa PROTECT-MI trial, moving its lead drug candidate Xolatryp into human testing for heart attack patients.

The trial represents the first clinical evaluation of Xolatryp in patients suffering ST-elevation myocardial infarction (STEMI), the most severe form of heart attack. The study is designed to assess whether the treatment can reduce additional heart muscle damage that may occur when blood flow is restored following an emergency intervention.

The first patient dosing marks the transition of Xolatryp from earlier laboratory, animal and healthy-volunteer studies into a patient-focused clinical trial.

Xolatryp Moves Into Phase IIa Heart Attack Study

Nyrada commenced dosing in the PROTECT-MI trial at Nepean Hospital in New South Wales and Sir Charles Gairdner Hospital in Western Australia.

The company is progressing additional Australian trial sites through governance approvals and has also indicated plans to expand the study into New Zealand.

PROTECT-MI is evaluating Xolatryp, an inhibitor of Transient Receptor Potential Canonical (TRPC) ion channels, in patients undergoing percutaneous coronary intervention (PCI). PCI is the standard emergency procedure used to reopen blocked coronary arteries during a heart attack.

The trial will assess safety, tolerability and early efficacy signals, with each patient followed for 30 days after treatment.

Targeting Heart Damage After Blood Flow Restoration

A key focus of the trial is ischaemia-reperfusion injury, a process where the restoration of blood flow to previously oxygen-deprived heart tissue can contribute to further cellular damage.

While PCI can restore circulation during a heart attack, additional injury may occur during the recovery process. Nyrada is developing Xolatryp as a potential treatment to address this secondary damage mechanism.

The company is testing whether TRPC channel inhibition may help reduce cellular stress responses linked to heart muscle injury.

No approved therapy currently specifically targets prevention of this type of secondary injury following STEMI, according to the company.

Trial Design Keeps Results Blinded Until Completion

The PROTECT-MI study is designed as a randomised, double-blind and placebo-controlled Phase IIa trial.

This means patients are assigned to treatment groups while both participants and investigators remain unaware of who receives active treatment or placebo until the trial reaches completion.

Because of the trial structure, efficacy results will not be available until the study is completed and unblinded.

Nyrada expects final patient dosing around mid-2027, with topline results anticipated approximately three months after the final patient completes the 30-day follow-up period.

Nyrada’s Broader TRPC Platform

Nyrada is developing small-molecule therapeutics targeting TRPC ion channels, which are involved in regulating calcium movement into cells during periods of stress or injury.

The company’s technology platform is focused on conditions where uncontrolled calcium influx may contribute to cell damage.

While Xolatryp’s current lead application is cardioprotection following heart attack, Nyrada is also progressing separate programs in cardiomyopathy and exploring other areas involving cellular stress and injury.

The company has also indicated plans to pursue a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA), with an IND application targeted for later in 2026.

Financial Position Supports Clinical Development

Nyrada reported a cash balance of approximately A$8.39 million as at 30 June 2026, with quarterly cash expenditure of around A$1.66 million.

The company has been funding its development activities as it advances clinical programs and regulatory engagement.

As the PROTECT-MI trial expands across additional sites and potential FDA activities progress, investors may continue monitoring future quarterly Cash Flow updates and expenditure levels.

What Comes Next for Xolatryp

The next stages of the PROTECT-MI program include activating additional trial sites, expanding recruitment opportunities and progressing the study towards final patient dosing.

Alongside the heart attack trial, investors may also watch developments related to Nyrada’s cardiomyopathy program and progress towards potential U.S. regulatory engagement.

The company’s future milestones are expected to focus on clinical execution, recruitment progress and eventual Phase IIa trial results.

Investor Takeaway

Nyrada’s first patient dosing milestone moves Xolatryp into a clinical setting for STEMI patients and provides the company with its first opportunity to evaluate the drug candidate in the intended patient population.

The milestone establishes a clinical pathway for the program, but future progress will depend on trial execution, patient recruitment, safety outcomes and efficacy results from the completed Phase IIa study.

Investors may continue watching trial expansion, regulatory activities and the timing of future clinical data updates as the program advances.